Related Experiment Video
Updated: Apr 21, 2026
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Pyrazole-Thiazole Hybrids: Synthesis and Biological Evaluation against Trypanosoma cruzi and Mycobacterium
Cynthia Nathália Pereira1, Lorraine Martins Rocha Orlando2, Edinaldo Castro de Oliveira2
1Laboratório de Síntese de Sistemas Heterocíclicos (LaSSH), Institute of Physics and Chemistry, Federal University of Itajubá, 1303 BPS Avenue, Pinheirinho, Itajubá, MG 37500-903, Brazil.
New pyrazole-thiazole compounds show promise against neglected tropical diseases. Compound 1g is effective against Trypanosoma cruzi, while 1h combats Mycobacterium tuberculosis, highlighting the role of halogen substitution.
Area of Science:
- Medicinal Chemistry
- Drug Discovery
- Parasitology
- Microbiology
Background:
- Neglected tropical diseases like Chagas disease (caused by Trypanosoma cruzi) and tuberculosis (caused by Mycobacterium tuberculosis) remain significant global health challenges.
- Pyrazole-thiazole hybrids represent a versatile scaffold with potential for developing novel therapeutic agents.
- Understanding the structure-activity relationships of these hybrids is crucial for optimizing their efficacy.
Purpose of the Study:
- To synthesize and characterize a series of pyrazole-thiazole hybrids.
- To evaluate the biological activity of these compounds against Trypanosoma cruzi and Mycobacterium tuberculosis.
- To investigate the impact of halogen substitution on the drug-like properties and biological performance of the hybrids.
Main Methods:
- Chemical synthesis of pyrazole-thiazole hybrids 1-(a-k).
- Physicochemical profiling to assess drug-like properties.
- In vitro biological assays to determine activity against Trypanosoma cruzi (trypomastigotes and amastigotes) and Mycobacterium tuberculosis (H37Rv strain).
- In silico analyses to explore binding interactions and stabilization of halogenated derivatives.
Main Results:
- Compound 1g (3-F) exhibited potent activity against Trypanosoma cruzi, with IC50 values of 11.66 μM and 26.83 μM for trypomastigotes and amastigotes, respectively.
- Compound 1h (4-Br) demonstrated significant antimycobacterial activity, with a Minimum Inhibitory Concentration (MIC) of 32.28 μM against the H37Rv strain.
- In silico studies indicated that halogen substitutions enhance stabilization through hydrophobic and π-driven interactions in enzymatic pockets.
Conclusions:
- Pyrazole-thiazole hybrids are promising scaffolds for developing new treatments against neglected parasitic and bacterial pathogens.
- Halogen substitution significantly influences the affinity and biological efficacy of these compounds.
- Further optimization, including exploring diverse halogen patterns and alternative binding sites, could lead to improved potency and selectivity.
